1 Neuroscience Education Institute, Carlsbad, California, USA.
CNS Spectr. 2013 Dec;18 Suppl 1:37-40; quiz 41. doi: 10.1017/S1092852913000758. Epub 2013 Nov 19.
There are several investigational drugs in development for the treatment of depression. Some of the novel antidepressants in development target monoaminergic neurotransmission in accordance with the "monoamine hypothesis of depression." However, the current conceptualization of antidepressant actions is that it is the downstream effects on protein synthesis and neuroplasticity that account for therapeutic efficacy, rather than the immediate effects on synaptic monoamine levels. Thus, a number of novel agents in development directly target components of this "neuroplasticity hypothesis of depression," including hypothetically overactive glutamatergic neurotransmission and dysfunctional hypothalamic-pituitary-adrenal (HPA) axis functioning.
目前有几种用于治疗抑郁症的研究性药物。一些正在开发的新型抗抑郁药针对单胺能神经传递，符合“抑郁症的单胺假说”。然而，目前对抗抑郁作用的概念化是，对蛋白质合成和神经可塑性的下游影响导致了治疗效果，而不是对突触单胺水平的即时影响。因此，许多正在开发的新型药物直接针对这一“抑郁症的神经可塑性假说”的组成部分，包括假设过度活跃的谷氨酸能神经传递和功能障碍的下丘脑-垂体-肾上腺（HPA）轴功能。
